Associate Scientist, Assay Development

---

Job description

OPPORTUNITY
Mammoth's Discovery Team is seeking an Associate Scientist to develop CRISPR-associated (Cas) nucleases for therapeutic genome editing applications. Discovery is a cross-disciplinary team of researchers responsible for the identification, screening and optimization of novel Cas nucleases. The successful candidate will be positioned in a downstream role within the team and will be responsible for pushing Cas nucleases into pre-clinical applications. Candidates with versatile technical skill sets are preferred for this role since a wide range of experimental approaches will be required to evaluate and enhance nuclease utility.
KEY RESPONSIBILITIES

• Drive development of cell-based and biochemical assay that are compatible with lab automation to characterize and optimize Cas nucleases for gene editing applications
• Independently plan, design and execute experiments
• Prepare protein, RNA and DNA reagents
• Document and present experimental results at internal meetings
• Other duties as assigned

REQUIRED QUALIFICATIONS

• B.S. in molecular biology, cell biology, synthetic biology or a related field
• 4 years biotechnology industry experience
• Hands-on experience developing cell-based and / or biochemical assays
• Familiarity with advanced laboratory equipment (eg. automated liquid handlers, automated colony pickers, plate readers, Flow cytometry / FACS)
• Experience independently designing and executing NGS assays

PREFERRED QUALIFICATIONS

• Prior experience with various methods for in vitro delivery of proteins and nucleic acids into mammalian cells.
• Familiarity with CRISPR-Cas literature
• Computer and scripting skills (Benchling, Geneious, JMP, SQL, R, Python)

BENEFITS

• Company-paid health/vision/dental benefits
• Unlimited vacation and generous sick time
• Company-sponsored meals and snacks
• Wellness, caregiver, and ergonomics benefits
• 401(k) with company matching

Mammoth Biosciences is harnessing the diversity of life to power the next generation of CRISPR products. Through the discovery and engineering of novel CRISPR systems, the company is enabling the full potential of its platform to read and write the code of life. Mammoth aims to develop permanent genetic cures through best-in-class in vivo and ex vivo therapies and to democratize disease detection with on-demand diagnostics. Mammoth can provide enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more. Based in the San Francisco Bay Area, Mammoth Biosciences is co-founded by CRISPR pioneer and Nobel Laureate Jennifer Doudna and Trevor Martin, Janice Chen, and Lucas Harrington. The firm is backed by top institutional investors including Redmile Group, Foresite Capital, Senator Investment Group, Sixth Street, Decheng, Mayfield, NFX, and 8VC, along with leading individual investors including Brook Byers, Tim Cook, and Jeff Huber.

TEAM
Our small-size proteins, such as Cas14 and CasPhi, are poised to transform disease treatment enabling novel editing approaches and delivery options that are difficult to achieve or not even possible with previously described CRISPR-Cas systems. Our teams are responsible for discovering and engineering novel CRISPR systems, establishing CRISPR-based diagnostics, and translating our unique CRISPR technology into therapeutic treatments with the ultimate goal of cures for indications with high medical need.

It is our policy and intent to provide equal opportunity to all persons without regard to race, color, religion, political affiliation, sex/gender (including gender expression/identity, pregnancy, childbirth and related medical conditions), marital status, registered domestic partner status, sexual orientation, age, ancestry, national origin, veteran status, disability, medical condition, genetic characteristics, and/or any other basis protected by law. This policy covers all facets of employment including, but not limited to: recruitment, selection, placement, promotions, transfers, demotions, terminations, training, and compensation.